Versant Capital Management »

Celldex Therapeutics shares owned by Versant Capital Management

Quarter-by-quarter ownership of Celldex Therapeutics (CLDX) shares owned by Versant Capital Management from 13F filings

Historical chart of Versant Capital Management investment in Celldex Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Celldex Therapeutics held by Versant Capital Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Celldex Therapeutics by Versant Capital Management

Quarter filed Position value Share count Share price at filing
2024-09-30 $3.1k 92 33.99

More positions owned by Versant Capital Management

Avantis International Equity Etf Etf (AVDE)
Vanguard Emerging Markets Government Bond Etf Etf (VWOB)
Avantis Emerging Markets Equity Etf Etf (AVEM)
Dimensional U.s. Core Equity 2 Etf Etf (DFAC)
Flexshares Tr Mornstar Upstr Etf (GUNR)
Ishares S&p Global Energy Etf (IXC)
Microsoft Stock (MSFT)
Vaneck Gold Miners Etf Etf (GDX)
Global X Fds Global X Ftse Greece 20 Etf Etf (GREK)
Dimensional International Core Equity 2 Etf Etf (DFIC)
Vanguard Total Stk Mkt Etf (VTI)
Exxon Mobil Corp Stock (XOM)
Spdr S&p Global Natural Resources Etf Etf (GNR)
Spdr Gold Minishares Trust Etf (GLDM)
Dimensional Us Marketwide Value Etf Etf (DFUV)

View all positions for Versant Capital Management

Top funds holding Celldex Therapeutics

BlackRock
BlackRock
Vanguard Group
Kynam Capital Management
Eventide Asset Management
Bellevue Group
T. Rowe Price Associates
State Street Corporation
Woodline Partners
T. Rowe Price Investment Management
Point72 Asset Management
Commodore Capital
Geode Capital Management
Rock Springs Capital Management
Jennison Associates

View all funds holding Celldex Therapeutics